A Call for Change: Updating the Operational Definition for Dementia in Parkinson's Disease.
作者信息
Kulisevsky Jaime, Litvan Irene, Weintraub Daniel, Goldman Jennifer G, Tröster Alexander I, Lewis Simon J G
机构信息
Movement Disorders Unit at the Neurology Department of Sant Pau Hospital, Universitat Autònoma de Barcelona, and CIBERNED, Bellaterra, Spain.
Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
出版信息
Mov Disord Clin Pract. 2025 Mar;12(3):296-301. doi: 10.1002/mdc3.14305. Epub 2024 Dec 17.
Abstract
摘要
相似文献
1
A Call for Change: Updating the Operational Definition for Dementia in Parkinson's Disease.变革的呼声：更新帕金森病痴呆的操作定义
Mov Disord Clin Pract. 2025 Mar;12(3):296-301. doi: 10.1002/mdc3.14305. Epub 2024 Dec 17.
2
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
3
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease.一年的练习效果可预测帕金森病的长期认知结果。
J Parkinsons Dis. 2025 Apr 29:1877718X251339585. doi: 10.1177/1877718X251339585.
4
Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.帕金森病认知衰退的遗传风险因素：文献综述。
Eur J Neurol. 2017 Apr;24(4):561-e20. doi: 10.1111/ene.13258. Epub 2017 Feb 21.
5
The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.雷瓦司汀对帕金森病早期神经精神症状的影响：系统评价。
Eur J Neurol. 2024 Feb;31(2):e16142. doi: 10.1111/ene.16142. Epub 2023 Nov 17.
6
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.来自法国E3N队列研究的女性中β-肾上腺素能受体药物的使用与帕金森病发病率
J Parkinsons Dis. 2025 Apr 29:1877718X251330993. doi: 10.1177/1877718X251330993.
7
Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS).早期帕金森病的痴呆风险预测：蒙特利尔帕金森痴呆风险量表（MoPaRDS）的验证与基因整合
J Parkinsons Dis. 2025 Apr 29:1877718X251329857. doi: 10.1177/1877718X251329857.
8
Knowledge and utilization of compensation strategies for Parkinson's disease in Dutch long-term care facilities: A survey among 130 healthcare professionals.荷兰长期护理机构中帕金森病补偿策略的知识与应用：对130名医护人员的调查
J Parkinsons Dis. 2025 Jun 26:1877718X251354928. doi: 10.1177/1877718X251354928.
9
Helicobacter pylori eradication for Parkinson's disease.根除幽门螺杆菌治疗帕金森病。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008453. doi: 10.1002/14651858.CD008453.pub2.
10
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.组织因子及其在帕金森病中的脑脊液蛋白谱。
J Parkinsons Dis. 2024;14(7):1405-1416. doi: 10.3233/JPD-240115.
引用本文的文献
1
Updates on Parkinson's Disease.帕金森病的最新进展
Neuropsychiatr Dis Treat. 2025 Sep 4;21:1945-1953. doi: 10.2147/NDT.S540718. eCollection 2025.
2
Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review.帕金森病神经精神症状的治疗方法：一项叙述性综述
Ther Adv Neurol Disord. 2025 May 26;18:17562864251336903. doi: 10.1177/17562864251336903. eCollection 2025.
本文引用的文献
1
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
2
Facilitating clinical use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative data and a diagnostic cutoff value.促进《阿姆斯特丹日常生活活动工具》在临床中的使用：常模数据和诊断截断值。
J Int Neuropsychol Soc. 2024 Jul;30(6):615-620. doi: 10.1017/S1355617724000031. Epub 2024 Mar 8.
3
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.通过脑脊液 alpha-突触核蛋白种子扩增检测法研究阿尔茨海默病中的 alpha-突触核蛋白共病理。
Alzheimers Dement. 2024 Apr;20(4):2444-2452. doi: 10.1002/alz.13658. Epub 2024 Feb 7.
4
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
5
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson's disease.脑脊液α-突触核蛋白种子扩增动力学曲线与帕金森病的认知衰退相关。
NPJ Parkinsons Dis. 2024 Jan 20;10(1):24. doi: 10.1038/s41531-023-00627-5.
6
Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease.血清神经丝蛋白表明晚期帕金森病患者神经退行性变加速，并可预测死亡率。
NPJ Parkinsons Dis. 2024 Jan 9;10(1):14. doi: 10.1038/s41531-023-00605-x.
7
Status of Current Biofluid Biomarkers in Parkinson's Disease.帕金森病当前生物流体生物标志物的现状
Mov Disord Clin Pract. 2023 May 19;10(Suppl 2):S18-S20. doi: 10.1002/mdc3.13753. eCollection 2023 Aug.
8
What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.名字意味着什么？将帕金森病和路易体痴呆统一起来的时机已经到来。
Mov Disord. 2023 Nov;38(11):1977-1981. doi: 10.1002/mds.29590. Epub 2023 Aug 23.
9
Same, same … but different!如出一辙……但又不尽相同！
Brain. 2023 Sep 1;146(9):3568-3570. doi: 10.1093/brain/awad241.
10
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.传播性 α-突触核蛋白种子作为突触核蛋白病的血清生物标志物。
Nat Med. 2023 Jun;29(6):1448-1455. doi: 10.1038/s41591-023-02358-9. Epub 2023 May 29.
Zotero 插件